Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus

A. R G Humphrey, D. J. McCarty, I. R. Mackay, M. J. Rowley, T. Dwyer, P. Zimmet

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We investigated the association of serum antibodies to glutamic acid decarboxylase (GADab) with early start of insulin treatment (≤ 1 year from diagnosis, or ≤ 2 years from diagnosis) using data from a representative sample of 374 adult-onset insulin-treated individuals from the Tasmanian Diabetes Register. Furthermore, we examined whether this association was stronger than the phenotypic characteristics (age at diagnosis, sex, family history of diabetes, level of obesity, duration of diabetes) often used for diabetes classification. In this cohort, 35.9% of males and 38.5% of females were GADab positive. Within the first year from diagnosis, 78.4% of GADab positive people compared to 44.0% of GADab negative people (p < 0.001) had started insulin treatment. Univariate associations with insulin treatment ≤ 1 year from diagnosis included GADab positivity, no family history of diabetes, lower BMI for men, and GADab positivity and lower BMI for women. In multivariate models, significant associations with insulin treatment ≤ 1 year from diagnosis included a family history of diabetes (OR = 0.47, 95% CI = 0.23-0.95) and GADab positivity (OR = 2.19, 95% CI = 1.01-4.73) for men, but only GADab positivity (OR = 7.53, 95% CI = 3.09-18.30) for women. Age at diagnosis was not associated with insulin treatment ≤ 1 year or ≤ 2 years from diagnosis for either sex. These findings indicate that a positive GADab test result is strongly associated with start of insulin treatment within 1 or 2 years from diagnosis, more so than characteristics such as level of obesity and age at diagnosis.

LanguageEnglish
Pages113-119
Number of pages7
JournalDiabetic Medicine
Volume15
Issue number2
DOIs
Publication statusPublished - 1998
Externally publishedYes

Keywords

  • Diabetes mellitus
  • Disease classification
  • Epidemiology
  • Glutamic acid decarboxylase
  • IDDM
  • NIDDM

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Humphrey, A. R G ; McCarty, D. J. ; Mackay, I. R. ; Rowley, M. J. ; Dwyer, T. ; Zimmet, P. / Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. In: Diabetic Medicine. 1998 ; Vol. 15, No. 2. pp. 113-119.
@article{7cb29ae444014c28a4d602831de01af1,
title = "Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus",
abstract = "We investigated the association of serum antibodies to glutamic acid decarboxylase (GADab) with early start of insulin treatment (≤ 1 year from diagnosis, or ≤ 2 years from diagnosis) using data from a representative sample of 374 adult-onset insulin-treated individuals from the Tasmanian Diabetes Register. Furthermore, we examined whether this association was stronger than the phenotypic characteristics (age at diagnosis, sex, family history of diabetes, level of obesity, duration of diabetes) often used for diabetes classification. In this cohort, 35.9{\%} of males and 38.5{\%} of females were GADab positive. Within the first year from diagnosis, 78.4{\%} of GADab positive people compared to 44.0{\%} of GADab negative people (p < 0.001) had started insulin treatment. Univariate associations with insulin treatment ≤ 1 year from diagnosis included GADab positivity, no family history of diabetes, lower BMI for men, and GADab positivity and lower BMI for women. In multivariate models, significant associations with insulin treatment ≤ 1 year from diagnosis included a family history of diabetes (OR = 0.47, 95{\%} CI = 0.23-0.95) and GADab positivity (OR = 2.19, 95{\%} CI = 1.01-4.73) for men, but only GADab positivity (OR = 7.53, 95{\%} CI = 3.09-18.30) for women. Age at diagnosis was not associated with insulin treatment ≤ 1 year or ≤ 2 years from diagnosis for either sex. These findings indicate that a positive GADab test result is strongly associated with start of insulin treatment within 1 or 2 years from diagnosis, more so than characteristics such as level of obesity and age at diagnosis.",
keywords = "Diabetes mellitus, Disease classification, Epidemiology, Glutamic acid decarboxylase, IDDM, NIDDM",
author = "Humphrey, {A. R G} and McCarty, {D. J.} and Mackay, {I. R.} and Rowley, {M. J.} and T. Dwyer and P. Zimmet",
year = "1998",
doi = "10.1002/(SICI)1096-9136(199802)15:2<113::AID-DIA528>3.0.CO;2-D",
language = "English",
volume = "15",
pages = "113--119",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "2",

}

Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus. / Humphrey, A. R G; McCarty, D. J.; Mackay, I. R.; Rowley, M. J.; Dwyer, T.; Zimmet, P.

In: Diabetic Medicine, Vol. 15, No. 2, 1998, p. 113-119.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus

AU - Humphrey, A. R G

AU - McCarty, D. J.

AU - Mackay, I. R.

AU - Rowley, M. J.

AU - Dwyer, T.

AU - Zimmet, P.

PY - 1998

Y1 - 1998

N2 - We investigated the association of serum antibodies to glutamic acid decarboxylase (GADab) with early start of insulin treatment (≤ 1 year from diagnosis, or ≤ 2 years from diagnosis) using data from a representative sample of 374 adult-onset insulin-treated individuals from the Tasmanian Diabetes Register. Furthermore, we examined whether this association was stronger than the phenotypic characteristics (age at diagnosis, sex, family history of diabetes, level of obesity, duration of diabetes) often used for diabetes classification. In this cohort, 35.9% of males and 38.5% of females were GADab positive. Within the first year from diagnosis, 78.4% of GADab positive people compared to 44.0% of GADab negative people (p < 0.001) had started insulin treatment. Univariate associations with insulin treatment ≤ 1 year from diagnosis included GADab positivity, no family history of diabetes, lower BMI for men, and GADab positivity and lower BMI for women. In multivariate models, significant associations with insulin treatment ≤ 1 year from diagnosis included a family history of diabetes (OR = 0.47, 95% CI = 0.23-0.95) and GADab positivity (OR = 2.19, 95% CI = 1.01-4.73) for men, but only GADab positivity (OR = 7.53, 95% CI = 3.09-18.30) for women. Age at diagnosis was not associated with insulin treatment ≤ 1 year or ≤ 2 years from diagnosis for either sex. These findings indicate that a positive GADab test result is strongly associated with start of insulin treatment within 1 or 2 years from diagnosis, more so than characteristics such as level of obesity and age at diagnosis.

AB - We investigated the association of serum antibodies to glutamic acid decarboxylase (GADab) with early start of insulin treatment (≤ 1 year from diagnosis, or ≤ 2 years from diagnosis) using data from a representative sample of 374 adult-onset insulin-treated individuals from the Tasmanian Diabetes Register. Furthermore, we examined whether this association was stronger than the phenotypic characteristics (age at diagnosis, sex, family history of diabetes, level of obesity, duration of diabetes) often used for diabetes classification. In this cohort, 35.9% of males and 38.5% of females were GADab positive. Within the first year from diagnosis, 78.4% of GADab positive people compared to 44.0% of GADab negative people (p < 0.001) had started insulin treatment. Univariate associations with insulin treatment ≤ 1 year from diagnosis included GADab positivity, no family history of diabetes, lower BMI for men, and GADab positivity and lower BMI for women. In multivariate models, significant associations with insulin treatment ≤ 1 year from diagnosis included a family history of diabetes (OR = 0.47, 95% CI = 0.23-0.95) and GADab positivity (OR = 2.19, 95% CI = 1.01-4.73) for men, but only GADab positivity (OR = 7.53, 95% CI = 3.09-18.30) for women. Age at diagnosis was not associated with insulin treatment ≤ 1 year or ≤ 2 years from diagnosis for either sex. These findings indicate that a positive GADab test result is strongly associated with start of insulin treatment within 1 or 2 years from diagnosis, more so than characteristics such as level of obesity and age at diagnosis.

KW - Diabetes mellitus

KW - Disease classification

KW - Epidemiology

KW - Glutamic acid decarboxylase

KW - IDDM

KW - NIDDM

UR - http://www.scopus.com/inward/record.url?scp=0031907502&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9136(199802)15:2<113::AID-DIA528>3.0.CO;2-D

DO - 10.1002/(SICI)1096-9136(199802)15:2<113::AID-DIA528>3.0.CO;2-D

M3 - Article

VL - 15

SP - 113

EP - 119

JO - Diabetic Medicine

T2 - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 2

ER -